aid: hillevax
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/hillevax.png
name: HilleVax
description: >-
  HilleVax was a clinical-stage biopharmaceutical company focused on developing
  and commercializing novel vaccines, most notably HIL-214, a virus-like-particle
  based vaccine candidate aimed at preventing moderate-to-severe acute
  gastroenteritis caused by norovirus infection. The company was surfaced in the
  API Evangelist network as a portfolio company of Lightspeed Venture Partners.
  Enrichment probing found no developer program, no API, no developer portal, and
  no public API documentation of any kind, which is expected for a clinical-stage
  vaccine developer rather than a technology/API producer. The company's primary
  domain (hillevax.com) now redirects to xoma.com (XOMA Royalty), indicating
  HilleVax has been acquired and wound down as an independent operating company;
  XOMA Royalty itself was subsequently acquired by Ligand (closed July 2026).
  This profile is retained as a company/identity record with no API surface.
url: https://raw.githubusercontent.com/api-evangelist/hillevax/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: no-api-surface
x-status: acquired
x-acquisition-note: hillevax.com redirects to xoma.com (XOMA Royalty); no developer/API surface exists.
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Vaccines
- Life Sciences
- Healthcare
- Norovirus
- Clinical Stage
common:
- type: Website
  url: https://www.hillevax.com
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1